<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312221</url>
  </required_header>
  <id_info>
    <org_study_id>BUP3019</org_study_id>
    <nct_id>NCT00312221</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain</brief_title>
  <official_title>Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the effectiveness and tolerability of the
      buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal
      system (5 mg) and oxycodone immediate release in subjects with moderate to severe
      osteoarthritis pain currently treated with oral opioids. The double-blind treatment
      intervention duration is 12 weeks during which time supplemental analgesic medication
      (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in
      addition to study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international
      clinical experience indicating it to be safe and effective in a variety of therapeutic
      situations for the relief of moderate to severe pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated early for administrative reasons unrelated to safety or efficacy
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Average Pain Over the Last 24 Hours&quot; Scores at Weeks 4, 8, and 12 of the Double-blind Phase.</measure>
    <time_frame>Weeks 4, 8, and 12 of the double-blind phase</time_frame>
    <description>The &quot;average pain over the last 24 hours&quot; score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Daily Number of Supplemental Analgesic Medication Tablets</measure>
    <time_frame>Double-blind phase (84 days)</time_frame>
    <description>The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase</measure>
    <time_frame>Weeks 4, 8 and 12 of the double-blind phase</time_frame>
    <description>The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete.
The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</measure>
    <time_frame>Weeks 4, 8, and 12 of the Double-blind Phase</time_frame>
    <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">418</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>BTDS 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTDS 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone Immediate-Release (Oxy IR) 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
    <arm_group_label>BTDS 5</arm_group_label>
    <other_name>Butrans™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
    <arm_group_label>BTDS 20</arm_group_label>
    <other_name>Butrans™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone immediate-release</intervention_name>
    <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
    <arm_group_label>Oxycodone Immediate-Release (Oxy IR) 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis of the hip, knee, or spine for 1 year or longer, confirmed by
             radiographic evidence within the last 2 years.

          -  Good pain control while on a stable dose of an opioid analgesic for osteoarthritis.

        Exclusion Criteria:

          -  Not currently taking and tolerating opioids.

          -  Taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days
             of enrollment.

          -  Requiring frequent analgesic therapy for chronic condition(s), in addition to
             osteoarthritis.

        Other protocol-specific exclusion/inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parkway Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Network</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Colorado Clinic</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Study Institute</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida, Inc.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research, Inc.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Medical Research Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non- Surgical Orthopedic &amp; Spine Center, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Biomedical Research, LLC</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miray Medical Center</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>23010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Clinical Research Crystal Lake Health Center</name>
      <address>
        <city>Benzonia</city>
        <state>Michigan</state>
        <zip>49616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology PC</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharm Quest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Search Professional Group/Pharmaceutical C-Trials Inc.</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Medical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2006</study_first_posted>
  <results_first_submitted>July 15, 2010</results_first_submitted>
  <results_first_submitted_qc>September 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2010</results_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, opioid, transdermal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Dates: 02-Apr-2004 (first subject first visit) to 18 Jul-2005 (last subject last visit); 15-Jun-2005 (first site notified of study termination). The study took place in 82 medical/research sites in the US; 59 sites randomized at least 1 subject.</recruitment_details>
      <pre_assignment_details>Men and women aged 40 years or older with OA of the hip, knee, or spine, on 30 to 80 mg/day morphine sulfate (MSO4) or equivalent, with or without nonopioid analgesic medication. (652 subjects entered the run-in period; 418 completed.) Subjects were eligible to enter the double-blind phase if they tolerated BTDS 20 and achieved stable analgesia.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Run-in Period</title>
          <description>The run-in period was designed to select subjects whose pain was adequately controlled by and who tolerated BTDS 20 treatment. BTDS 10 or 20 was applied for 7-day wear during the 3-week run-in period.</description>
        </group>
        <group group_id="P2">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="P3">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="P4">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="652"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="418"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not qualify</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="149"/>
                <participants group_id="P4" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="B2">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
        </group>
        <group group_id="B3">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="133"/>
            <count group_id="B4" value="418"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="10.71"/>
                    <measurement group_id="B2" value="57.9" spread="9.45"/>
                    <measurement group_id="B3" value="58.1" spread="10.36"/>
                    <measurement group_id="B4" value="58.3" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>“Average Pain Over the Last 24 Hours” Scores at Weeks 4, 8, and 12 of the Double-blind Phase.</title>
        <description>The “average pain over the last 24 hours” score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).</description>
        <time_frame>Weeks 4, 8, and 12 of the double-blind phase</time_frame>
        <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>“Average Pain Over the Last 24 Hours” Scores at Weeks 4, 8, and 12 of the Double-blind Phase.</title>
          <description>The “average pain over the last 24 hours” score was collected using an 11-point numerical scale ranging from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. This variable was obtained at each clinic visit during the double-blind phase of the study (postrandomization weeks 1, 2, 4, 8, and 12).</description>
          <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="0.116"/>
                    <measurement group_id="O2" value="6.58" spread="0.103"/>
                    <measurement group_id="O3" value="6.44" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.114"/>
                    <measurement group_id="O2" value="3.02" spread="0.093"/>
                    <measurement group_id="O3" value="3.03" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="0.219"/>
                    <measurement group_id="O2" value="3.57" spread="0.195"/>
                    <measurement group_id="O3" value="3.45" spread="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="0.239"/>
                    <measurement group_id="O2" value="3.37" spread="0.190"/>
                    <measurement group_id="O3" value="3.59" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.246"/>
                    <measurement group_id="O2" value="3.56" spread="0.230"/>
                    <measurement group_id="O3" value="3.37" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8562</ci_lower_limit>
            <ci_upper_limit>0.1054</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 20 and BTDS 5 during the 12-week double-blind phase</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8455</ci_lower_limit>
            <ci_upper_limit>0.1189</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Daily Number of Supplemental Analgesic Medication Tablets</title>
        <description>The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.</description>
        <time_frame>Double-blind phase (84 days)</time_frame>
        <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Daily Number of Supplemental Analgesic Medication Tablets</title>
          <description>The mean daily number of supplemental analgesic medication tablets included sponsor-supplied ibuprofen, acetaminophen, or OxyIR®.</description>
          <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>Tablets</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.19"/>
                    <measurement group_id="O2" value="1.7" spread="0.13"/>
                    <measurement group_id="O3" value="1.6" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-blind</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.26"/>
                    <measurement group_id="O2" value="2.3" spread="0.19"/>
                    <measurement group_id="O3" value="2.3" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase</title>
        <description>The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete.
The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).</description>
        <time_frame>Weeks 4, 8 and 12 of the double-blind phase</time_frame>
        <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>The Physical Function Subscale of The Western Ontario and McMaster's Universities Osteoarthritis (WOMAC OA) Index at Weeks 4, 8, and 12 of the Double Blind Phase</title>
          <description>The WOMAC (Version LK 3.1) measures symptoms and physical functioning of patients with OA of the hip and knee. It contains 24 items (5 pain, 2 stiffness, 17 physical function) and takes less than 5 minutes to complete.
The WOMAC physical function subscale has 17 items coded as 0 to 4 (best to worst), which are summed, giving a range of 0 to 68 (best to worst).</description>
          <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.88" spread="1.093"/>
                    <measurement group_id="O2" value="37.69" spread="0.930"/>
                    <measurement group_id="O3" value="36.81" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.96" spread="0.993"/>
                    <measurement group_id="O2" value="24.19" spread="0.947"/>
                    <measurement group_id="O3" value="24.42" spread="0.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.60" spread="1.187"/>
                    <measurement group_id="O2" value="28.34" spread="1.025"/>
                    <measurement group_id="O3" value="26.65" spread="1.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.70" spread="1.364"/>
                    <measurement group_id="O2" value="28.34" spread="1.199"/>
                    <measurement group_id="O3" value="26.59" spread="1.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.68" spread="1.500"/>
                    <measurement group_id="O2" value="29.35" spread="1.253"/>
                    <measurement group_id="O3" value="27.25" spread="1.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.707</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0054</ci_lower_limit>
            <ci_upper_limit>2.0397</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.187</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4459</ci_lower_limit>
            <ci_upper_limit>0.8706</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</title>
        <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
        <time_frame>Weeks 4, 8, and 12 of the Double-blind Phase</time_frame>
        <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind BTDS 5</title>
            <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O2">
            <title>Double-blind BTDS 20</title>
            <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear</description>
          </group>
          <group group_id="O3">
            <title>Double-blind Oxycodone Immediate-Release</title>
            <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).</description>
          </group>
        </group_list>
        <measure>
          <title>The Sleep Disturbance Subscale in The Medical Outcomes (MOS)-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase</title>
          <description>The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity of optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 and Questions 2 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.</description>
          <population>Full Analysis Population (N = 418) consisted of subjects who were randomized and received at least 1 dose of double-blind study drug.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.91" spread="2.139"/>
                    <measurement group_id="O2" value="55.28" spread="2.035"/>
                    <measurement group_id="O3" value="55.74" spread="2.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prerandomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.64" spread="1.950"/>
                    <measurement group_id="O2" value="28.65" spread="1.782"/>
                    <measurement group_id="O3" value="33.03" spread="1.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.23" spread="2.144"/>
                    <measurement group_id="O2" value="32.40" spread="1.941"/>
                    <measurement group_id="O3" value="35.72" spread="2.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.95" spread="2.791"/>
                    <measurement group_id="O2" value="31.71" spread="2.473"/>
                    <measurement group_id="O3" value="34.13" spread="2.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.13" spread="3.089"/>
                    <measurement group_id="O2" value="32.95" spread="2.819"/>
                    <measurement group_id="O3" value="36.32" spread="3.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6177</ci_lower_limit>
            <ci_upper_limit>3.6930</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and BTDS 20 during the 12-week double-blind phase.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4415</ci_lower_limit>
            <ci_upper_limit>2.8255</ci_upper_limit>
            <estimate_desc>Treatment comparison between BTDS 5 and oxycodone immediate-release during the 12-week double-blind phase.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) occurring after the signing of informed consent up to study completion or discontinuation; during 7 days after last visit; serious AEs up to 30 days following the last study visit were followed until the event resolved.</time_frame>
      <desc>AEs were obtained through spontaneous reports and subject interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Double-blind BTDS 5</title>
          <description>Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
        </group>
        <group group_id="E2">
          <title>Double-blind BTDS 20</title>
          <description>Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear during the 12-week double-blind phase</description>
        </group>
        <group group_id="E3">
          <title>Double-blind Oxycodone Immediate-Release</title>
          <description>Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours) during the 12-week double-blind phase.</description>
        </group>
        <group group_id="E4">
          <title>Run-in, Open-label BTDS 10 and 20</title>
          <description>The run-in period was designed to select subjects whose pain was adequately controlled by and who tolerated BTDS 20 treatment. BTDS 10 or 20 was applied for 7-day wear during the 3-week run-in period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Chest pain with ischemic episode</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Paroxysmal supraventricular tachycardia</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid ovarian cyst</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Exacerbation of Crohn's disease</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>GI bleeding</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Acid reflux</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Systematic and nonsystematic assessment
&quot;Fall&quot; and &quot;Fell&quot; are listed as 2 separate categories.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Fell</sub_title>
                <description>Systematic and nonsystematic assessment
&quot;Fall&quot; and &quot;Fell&quot; are listed as 2 separate categories.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured left hip</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Postsurgical hip joint dislocation, left hip</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms right knee</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Recurrent L4-L5 disc herniation</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">End stage OA of the right knee</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Liver cancer</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Possible bone cancer</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Prostatic adenocarcinoma</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of lumbar spinal stenosis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Recurrent L5-S1 disc herniation with impingement of the S1 nerve root</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Transischemic attack</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Enlarged uterus</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Worsening asthma</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>OxyIR abuse</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Systematic and nonsystematic assessment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="187" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <description>Systematic and nonsystematic assessments</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="652"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Systematic and nonsystematic assessments.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="652"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early for administrative reasons not related to safety or efficacy. Low enrollment at termination led to reduced power.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Leader, Medical Director</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

